KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Gains from Sales and Divestitures (2016)

Historic Gains from Sales and Divestitures for AbbVie (ABBV) over the last 4 years, with Q2 2016 value amounting to $6.1 million.

  • AbbVie's Gains from Sales and Divestitures rose 1115.54% to $6.1 million in Q2 2016 from the same period last year, while for Jun 2016 it was $6.1 million, marking a year-over-year increase of 1115.54%. This contributed to the annual value of $5.7 million for FY2015, which is 1410.06% down from last year.
  • Latest data reveals that AbbVie reported Gains from Sales and Divestitures of $6.1 million as of Q2 2016, which was up 1115.54% from $5.5 million recorded in Q1 2016.
  • In the past 5 years, AbbVie's Gains from Sales and Divestitures ranged from a high of $7.6 million in Q4 2013 and a low of $5.3 million during Q1 2015
  • In the last 4 years, AbbVie's Gains from Sales and Divestitures had a median value of $6.3 million in 2014 and averaged $6.4 million.
  • Per our database at Business Quant, AbbVie's Gains from Sales and Divestitures plummeted by 1453.25% in 2015 and then skyrocketed by 1115.54% in 2016.
  • AbbVie's Gains from Sales and Divestitures (Quarter) stood at $7.6 million in 2013, then dropped by 12.11% to $6.6 million in 2014, then fell by 14.1% to $5.7 million in 2015, then grew by 7.65% to $6.1 million in 2016.
  • Its Gains from Sales and Divestitures stands at $6.1 million for Q2 2016, versus $5.5 million for Q1 2016 and $5.7 million for Q4 2015.